Month: July 2026

Release – Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01

Posted on by [email protected]
Greenwich LifeSciences

Research News and Market Data on GLSI

 Download as PDF

July 16, 2026 7:30am EDT

STAFFORD, Texas, July 16, 2026 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the combination of both HLA-A*02 and non-HLA-A*02 patients in FLAMINGO-01 in Europe.

All European and US Sites to Combine All Patients Independent of HLA Type in the Randomized Arms of FLAMINGO-01

The Company previously announced that US clinical sites started enrolling both HLA-A*02 and non-HLA-A*02 patients in the same randomized arms in FLAMINGO-01, based on the FDA’s review of such protocol changes, effectively more than doubling the enrollment rate of the pivotal arm of the study. Non-HLA-A*02patients who represent about 55% of the population and were on waiting lists for up to a year are now eligible for enrollment.

The European Medicines Agency (EMA) has completed their review and will also allow the combination of both HLA-A*02 and non-HLA-A*02 patients in Europe. Thus, all 170-180 clinical sites in the US and Europe, are now operating under the same protocol and could continue enrolling up to the first interim analysis. Data can be analyzed by individual HLA types as well.

Additional feedback is expected from UK and Canadian regulators. The Company plans to provide updates regarding the resulting improved trial design, including a pathway for the Company to now pursue approval for both HLA-A*02 and non-HLA-A*02 patients using the increased statistical power of a combined analysis of the two patient groups together potentially doubling the market for GP2 by accelerating the clinical development of the non-HLA-A*02 population.

About FLAMINGO-01 Open Label Phase III Data

More than 1,300 patients have been screened with a current screen rate of approximately 800 patients per year. The 250 patient non-HLA-A*02 arm is now fully enrolled, where all patients received GLSI-100, which is 5 times more treated patients and recurrence rate data than the approximately 50 patients treated in the Phase IIb trial. The Primary Immunization Series (PIS), which includes the first 6 GLSI-100 injections over the first 6 months and is required to reach peak protection, is followed by 5 booster injections given every 6 months to prolong the immune response, thereby providing longer-term protection.

  • In the non-HLA-A*02 arm, a preliminary analysis of recurrence rates after the PIS is completed shows an approximately 70-80% reduction in recurrence rate.
  • This observation is trending similarly to the Phase IIb trial results and hazard ratio where HLA-A*02 patients were treated and where breast cancer recurrences were reduced up to 80% compared to a 20-50% reduction in recurrence rate by other approved products.
  • The immune response at baseline prior to any GLSI-100 treatment, the increasing immune response during the PIS, and the safety profile of non-HLA-A*02 patients is trending similarly to the HLA-A*02 arms of FLAMINGO-01 and to the Phase IIb study.
    • The AACR Meeting 2026 delayed-type-hypersensitivity (DTH) poster and the ASCO Meeting 2026 injection site reaction (ISR) poster can be seen and downloaded at the bottom of the Phase III clinical trial tab on the Company’s website here.
    • As shown in both posters the frequency of DTH and ISR reactions increased statistically significantly over time.
    • As reported in Table 1 of each poster, each HLA-A type exhibited more frequent immune reactivity after treatment with GLSI-100 than at baseline.
    • Baseline DTH reaction prior to any treatment suggests that GP2 may be a natural antigen and that GP2 specific T cells may exist in some patients prior to any treatment with GLSI-100. Baseline immune response to GP2 prior to any vaccination with GP2 was also observed in the Phase IIb trial and is being observed in the blinded randomized arms of FLAMINGO-01, where HLA-A*02 only patients are being vaccinated.

Analysis of the open label data from FLAMINGO-01 has been conducted in a manner that maintains the study blind. The open label recurrence rate, immune response, and safety data is based on the patients enrolled to date in FLAMINGO-01 and the data provided by the clinical sites so far, which is not completed or fully reviewed, and is thus preliminary. While comparing any preliminary FLAMINGO-01 data to the Phase IIb clinical trial data may be possible, these preliminary results are not a prediction of future results, and the results at the end of the study may differ.

About GLSI-100 Phase IIb Study

In the prospective, randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial of HLA-A*02 breast cancer patients, 46 HER2/neu 3+ over-expressor patients were treated with GLSI-100, and 50 placebo patients were treated with GM-CSF alone. After 5 years of follow-up, there was an 80% or greater reduction in cancer recurrences in the HER2/neu 3+ patients who were treated with GLSI-100, followed, and remained disease free over the first 6 months, which we believe is the time required to reach peak immunity and thus maximum efficacy and protection. The Phase IIb posters and results can be summarized as follows and can be seen here:

  • 80% or greater reduction in metastatic breast cancer recurrence rate over 5 years of follow-up with a peak immune response at 6 months and well-tolerated safety profile.
  • The PIS elicited a potent immune response as measured by local skin tests and immunological assays.

About FLAMINGO-01 and GLSI-100

FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of Fast Track designated GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 170-180 sites globally.

About Breast Cancer and HER2/neu Positivity

One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels.

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company’s website at www.greenwichlifesciences.com and follow the Company’s Twitter at https://twitter.com/GreenwichLS.

Forward-Looking Statement Disclaimer

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled “Risk Factors” in Greenwich LifeSciences’ Annual Report on the most recent Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.

Company Contact
Snehal Patel
Investor Relations
Office: (832) 819-3232
Email: [email protected]

Investor & Public Relations Contact for Greenwich LifeSciences
Dave Gentry
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Email: [email protected]

Primary Logo

Source: Greenwich LifeSciences, Inc.

Released July 16, 2026

Eli Lilly Pays $3.8 Billion for AtaiBeckley as Big Pharma’s Push Into Mental Health Enters a New Phase

Posted on by [email protected]

The pharmaceutical industry’s appetite for neuroscience innovation just produced one of the most significant mental health deals in years. Eli Lilly (NYSE: LLY) announced Wednesday it has entered into a definitive agreement to acquire AtaiBeckley (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing rapid-acting therapies for treatment-resistant depression and other serious mental health conditions. The deal values AtaiBeckley at approximately $2.8 billion in upfront equity consideration, with an additional $1.0 billion in potential milestone-based contingent value rights, bringing the total potential transaction value to approximately $3.8 billion.

AtaiBeckley shareholders will receive $6.75 per share in cash at closing, representing a 40% premium to the stock’s 30-day volume-weighted average trading price. The contingent value rights are tied to specific development and regulatory milestones across the company’s two most advanced programs. The transaction is expected to close in the third quarter of 2026.

What Lilly Is Acquiring

AtaiBeckley’s pipeline is built around a class of compounds called rapid-acting neuroplastogens, therapies designed to restore the brain’s ability to form and strengthen neural connections in regions critical to mood regulation. This is a fundamentally different approach from conventional antidepressants, which primarily target neurotransmitter levels. The distinction matters because treatment-resistant depression, by definition, persists after multiple conventional treatments have failed. Millions of Americans live with it, and the clinical need for a genuinely new mechanism of action is substantial.

The lead asset, BPL-003, is a synthetic form of 5-MeO-DMT delivered as a nasal spray. In a Phase 2b study, the compound demonstrated rapid and durable reductions in depressive symptoms following a single in-clinic visit lasting approximately two hours on average, with beneficial effects persisting for months. The FDA has granted BPL-003 Breakthrough Therapy Designation and Phase 3 activities are already underway.

The second program, VLS-01, is a buccal film formulation of DMT currently advancing in a Phase 2b study for treatment-resistant depression. A third asset, EMP-01, is an R-MDMA compound in Phase 2 development for social anxiety disorder. Together, the pipeline represents one of the most clinically advanced portfolios in the emerging psychedelic-derived therapeutics space.

The Bigger Picture for Neuroscience M&A

Lilly’s move into mental health through the AtaiBeckley acquisition reflects a growing recognition across the pharmaceutical industry that neuroscience, and specifically psychiatry, represents one of the largest underserved therapeutic markets remaining. The company framed the deal explicitly as an expansion of its neuroscience pipeline to address conditions where existing treatments consistently fall short.

The deal structure itself reveals how large pharma is approaching risk in this space. The $2.8 billion upfront payment secures the pipeline and the Phase 3 asset immediately. The $1.0 billion in CVRs ties additional payments to clearly defined regulatory and development milestones, aligning incentives between buyer and seller while limiting downside if programs do not advance as planned.

What It Signals for Small Cap Biotech

For investors tracking clinical-stage neuroscience and CNS-focused companies in the small and microcap space, the Lilly-AtaiBeckley transaction sends a direct signal. Large pharma is now willing to pay nearly $4 billion for a pre-revenue mental health company with Breakthrough Therapy Designation and Phase 3 readiness. That valuation framework applies to other companies advancing differentiated CNS programs through mid-to-late-stage development, including names like NeuroSense Therapeutics, both of which are developing therapies targeting neurological and psychiatric conditions with significant unmet need.

The biotech M&A wave that began with GSK-Nuvalent and AbbVie-Apogee earlier this year has now expanded beyond oncology into neuroscience. The message from large pharma is consistent: validated clinical data, Breakthrough Therapy Designation, and clear regulatory paths in large patient populations are commanding premium valuations regardless of therapeutic area. The pipeline of small cap companies fitting that profile remains deep.

The GEO Group (GEO) – New Contract with ICE; Raising Price Target

Posted on by [email protected]


Thursday, July 16, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New Contract. The GEO Group has entered into a five-year support services contract with U.S. Immigration and Customs Enforcement (“ICE”) for the activation of a federal immigration processing center at the 1,188-bed Big Horn Facility. GEO has entered into a lease agreement with the Facility owner. We view the new award positively and expect to see more such announcements going forward as ICE continues to seek out partners to assist the Agency in fulfilling its mission.

Details. The support services contract is expected to generate approximately $85 million in annual revenues in the first full year of operations, excluding transportation revenue. GEO’s support services are expected to include the exclusive use of the facility by ICE, along with security, maintenance, and food services, as well as access to recreational amenities, medical care, and legal counsel.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

T3 Defense (DFNS) – Reverse Split

Posted on by [email protected]


Thursday, July 16, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Reverse Split. T3 is implementing a 50-for-1 reverse stock split. The reverse stock split will become effective as of 12:01 a.m., Eastern Time, on July 20, 2026, and the Company’s common stock will begin trading on the Nasdaq Global Market on a split-adjusted basis when the market opens on July 20, 2026.

Rationale. The Company is implementing the reverse stock split to raise the per-share bid price of the Company’s common stock above $1.00 per share and bring the Company back into compliance with Nasdaq Listing Rule 5550(a). The Company will have regained compliance once the Company’s shares trade at or above $1.00 for a minimum of 10 consecutive trading days, at which time Nasdaq will provide the Company with notice that it has regained compliance.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Power Metallic Mines Inc. (PNPNF) – Advancing the Nisk Project Toward Development

Posted on by [email protected]


Thursday, July 16, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Building Momentum. Power Metallic is advancing the Nisk Project from exploration toward development, with a maiden NI 43-101 mineral resource estimate expected by the end of July 2026, followed by a Preliminary Economic Assessment which we anticipate could be completed in December 2026. The addition of mining executive Mr. Christopher Beal as Vice President of Operations further strengthens the company’s technical and operational capabilities as it progresses toward engineering studies and future development.

Drilling Continues to Deliver. Recent drilling reinforced the exceptional quality of the Lion Zone, highlighted by an intercept of 36.42 meters grading 2.83% copper equivalent, including 6.0 meters grading 12.38% copper equivalent. Combined with consistently high-grade drill results, strong metallurgical recoveries, and multiple target areas, the Nisk Project has the potential to become a significant polymetallic mining district.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

CoreCivic, Inc. (CXW) – Redeeming 4.75% Notes

Posted on by [email protected]


Thursday, July 16, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Redemption. CoreCivic has elected to redeem in full the 4.75% Senior Notes due 2027 that remain outstanding on August 12, 2026. This was an expected use of funds from the recently announced sale of two facilities to the Federal government. As of July 13, 2026, the principal amount of the outstanding 2027 Notes was $238,468,000. We anticipate additional debt reduction with a portion of the remaining sale proceeds.

Detail. The 2027 Notes will be redeemed at a redemption price equal to 100.000% of the principal amount of the then-outstanding 2027 Notes, plus the applicable “make-whole” premium specified in the indenture, as supplemented, governing the 2027 Senior Notes, plus accrued and unpaid interest to, but not including, the Redemption Date. We estimate the annual interest expense savings to be approximately $11.3 million.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Century Lithium Corp. (CYDVF) – Century Lithium Advances Commercial Readiness

Posted on by [email protected]


Thursday, July 16, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Angel Island Lithium Carbonate to High-Purity Lithium Metal. Century Lithium announced that lithium carbonate produced from its wholly owned Angel Island Lithium Project in Nevada was successfully converted into high-purity lithium metal by Alpha-En Corporation using its proprietary extraction and electrodeposition technology and subsequently incorporated into cylindrical battery cells manufactured by EaglePicher Technologies. The work was completed under the U.S. Army Small Business Innovation Research (SBIR) program, which supports the development of technologies critical to national defense.

Strong Battery Performance. Testing demonstrated that the lithium metal anodes met EaglePicher’s performance specifications and delivered higher operating voltages and improved power performance compared with control cells. These results highlight the suitability of Angel Island lithium for advanced, high-energy battery applications while validating the project’s potential to supply a domestic source of battery-grade lithium for defense-related technologies.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

The Strait of Hormuz Recovery Just Collapsed. Oil Flows Are Back Near Wartime Lows

Posted on by [email protected]

The brief window of optimism that followed the US-Iran ceasefire is closing fast. Oil shipments through the Strait of Hormuz, which had recovered to roughly 50% of pre-war levels under the June 17 memorandum of understanding, have fallen sharply over the past week as the ceasefire arrangement fell apart and active fighting resumed between US and Iranian military forces. According to Goldman Sachs, flows through the strait have dropped back to an estimated 3 to 5 million barrels per day, down from approximately 10 million barrels per day in early July.

The reversal leaves the global oil market short roughly 13.4 million barrels per day of Gulf supply, a deficit that is already showing up at the pump and in the price of crude. Brent crude has jumped more than 8% over the past five trading sessions to trade back above $84 per barrel. WTI has climbed more than 8% to above $79. Both benchmarks are moving in the wrong direction for an economy that had only just begun pricing in a post-war energy recovery.

What Went Wrong

The MOU signed June 17 was supposed to reopen the strait to pre-war commercial traffic within 30 days and establish a framework for broader negotiations. For roughly four weeks, that framework held. Tanker crossings increased, oil prices declined sharply, and the global economy began adjusting to a lower energy cost environment. Gas prices fell below $4 nationally for the first time in months.

That progress has now reversed. US Central Command announced a new wave of strikes against Iranian military targets Wednesday, the fifth consecutive day of US military action in the region. Iran has continued retaliating with attacks against US installations throughout the Gulf. A second US naval blockade of the strait, which began Tuesday evening, has already redirected commercial vessels attempting to transit the waterway. Energy market analysts at Rystad Energy have stated that expectations for near-term flow normalization have failed to materialize, and the latest escalation has further reduced the probability of a recovery in the weeks ahead.

The Small Cap Squeeze Returns

For investors in the sub-$2 billion market cap space, this reversal hits on two fronts simultaneously. The consumer-facing small caps that had only just begun to benefit from lower fuel costs are now watching that relief evaporate. Companies in transportation, logistics, food service, and retail, including names like ONE Group Hospitality and Travelzoo, are right back in the margin compression environment that characterized the spring. Diesel prices, which had been trending lower, are poised to reverse alongside crude if the strait remains effectively closed.

On the other side of the trade, domestic energy producers are seeing the price environment strengthen again. Independent oil and gas operators, including names like InPlay Oil and Alliance Resource Partners, along with midstream players like Summit Midstream Partners, benefit directly from sustained crude prices above $80. The economics for US producers improve at every dollar WTI moves higher, and the re-escalation removes the near-term risk that a permanent peace deal would collapse prices back toward pre-war levels.

Goldman Sachs strategists have cautioned that recovery this time could be slower than the initial post-ceasefire rebound, given depleted global inventories and continued shipper reluctance to route through the region even via Omani waters. China, the world’s largest crude importer, had reduced its intake by 5 million barrels per day during the first phase of the conflict, but that restraint could shift as Gulf producers adjust pricing and Beijing reassesses its long-term stockpile strategy.

The ceasefire was supposed to be the beginning of the end. Instead, the strait is closing again, and the energy cost pressure that defined the first half of 2026 is threatening to define the second half as well.

Release – Power Metallic reports New Lion drill intercepts of 36.42 Meters of 2.83% CuEqRec1 in Hole 26-116 including 6.00 Meters of 12.38% CuEqRec1 and Announces AGSM Meeting Results

Posted on by [email protected]
Power Metallic Logo

Research News and Market Data on PNPNF

TORONTO, July 15, 2026 – Power Metallic Mines Inc. (the “Company” or “Power Metallic”) (TSXV: PNPN) (OTCBB: PNPNF) (Frankfurt: IVV1) is pleased to provide final assay results from its Winter 2026 drill program and the voting results from its Annual General and Special Meeting (“AGSM“) held on June 30, 2026, in Toronto, Ontario.

Summary

These assays from Power Metallic’s winter 2026 drill program complete the drill results to be used for the initial NI-43-101 Mineral Resource Estimate (MRE) on Lion. Completion and reporting of the MRE estimates on Lion and the Nisk deposit is scheduled for the end of July. This MRE will form the basis for a Preliminary Economic Assessment (PEA) to begin immediately following the completion of the MRE.

Lion Zone MRE In-fill program

This news release includes drill holes defining the eastern side of the Lion Zone close to surface (Figure 1). All holes are in preparation for the 2026 Mineral Resource Estimate (MRE). The infill drill holes in this release were drilled to delimit the eastern side of Lion to increase the confidence of modelling the zone, particularly within the range of a potential future open pit.

In-fill drill holes in the shallow central parts of the deposit continue to report good near surface grades as evidenced by PML-26-116 which intersected high-grade copper near surface with 36.42 m @ 2.83% CuEqRec1 at 75m below surface, including semi-massive mineralization with 6.00 m @ 12.38% CuEqRec1. (Table 1 and Figure 1).

Drill holes included in Figure 1 but not in the table of Lion results (Table 1) occur on the eastern side of Lion, delimiting the eastern edge for MRE resource modelling. These holes did intersect the favourable mineralized structure, but had low grade assays, including individual assays of up to 0.49 g/t Pt and 0.62 g/t Pd, as well as anomalous Cu and Au, defining the mineralized structure’s location. Two holes also tested near surface between Lion and Tiger, again intersecting the mineralized structure with weak Cu, Pd results.

Table 1: Final Lion Results – Winter 2026
HoleFromToLengthAuAgCuPdPtNiCuEq Rec*
(m)(m)(m)(g/t)( g/t )( %)(g/t)( g/t )( %)( %)
PML-26-080125.50150.1824.680.135.480.290.07––0.49
Including128.34131.553.210.318.150.870.04––1.18
PML-26-083a135.30140.154.850.152.240.071.320.900.031.12
PML-26-10766.0070.004.000.238.500.250.03––0.52
PML-26-10839.0065.0026.000.104.610.17–––0.30
PML-26-11136.0050.0014.000.125.520.460.760.02–0.96
Including47.0049.002.000.259.951.413.710.12–3.36
and64.4067.122.720.143.610.300.420.060.070.76
PML-26-11316.5061.0044.500.603.480.200.130.02–0.75
Including34.0048.5014.501.636.060.340.200.02–1.70
and including47.6948.500.8126.406.700.792.430.250.0821.39
PML-26-11684.00120.4236.420.3010.171.202.340.480.092.83
Including98.50104.506.000.9645.486.109.151.680.4312.38
and including114.50118.574.070.596.230.645.821.510.124.30
1Copper Equivalent Rec Calculation (CuEqRec1)
CuEqRec represents CuEq calculated based on the following metal prices (USD) : 2,360.15 $/oz Au, 27.98 $/oz Ag, 1,215.00 $/oz Pd, 1000.00 $/oz Pt, 4.00 $/lb Cu, 10.00 $/lb Ni and 22.50 $/lb Co., and recovered grades based on recent locked-cycle metallurgical recoveries by SGS Canada Inc (see press release Jan 21, 2006).
2 Reported length is downhole distance; true width based on model projections is estimated as 85% of downhole length

Power Metallic is expecting more assay results from the summer drilling program, including regional exploration in the weeks to come.

Annual General and Special Meeting Results

Power Metallic’s held its AGSM on June 30, 2026, in Toronto, Ontario.

Shareholders voted in favor of all items of business presented at the AGSM, as outlined in the proxy-related materials, including the Notice of Meeting and the Information Circular dated May 15, 2026 (the “Information Circular“). These items included the election of directors such that each of Terry Lynch, Peter Kent, Les Mallard, Greg McKenzie, Steve Beresford, and Seamus O’Regan were elected as directors, the appointment of the Company’s auditor, MNP LLP, the re- approval of the Omnibus Equity Incentive Plan, and the approval of an amendment to the Company’s Articles to increase the quorum threshold for shareholder meetings. Just over 33.42% of the Company’s issued and outstanding common shares as of the record date of the AGSM were voted. For more information on the resolutions and the Omnibus Equity Incentive Plan, shareholders are encouraged to refer to the Information Circular available at the Company’s profile on SEDAR+.

The shareholder approval of the Articles’ amendment to increase the quorum threshold for shareholder meetings to 33-1/3%, will allow the Company’s Articles to meet the quorum threshold expected for companies listed on a U.S. national stock exchange. With shareholder approval in hand, and as disclosed in the Information Circular, the Company intends to implement the Articles amendment at such time as the Board of Directors has determined to proceed with seeking a listing on a U.S. national stock exchange.

The full scrutineer’s report for the AGM votes will be posted on the company’s website by the end of the week at the following address: https://www.powermetallic.com/financial_statements/.

“We are grateful for the strong support of our shareholders at this year’s Annual General and Special Meeting. Receiving approval for the amendment to our Articles to align our quorum threshold with U.S. national exchange requirements is a meaningful step forward in our mission to bring Power Metallic’s story to a broader investor audience. With the Lion Zone delivering some of the highest-grade polymetallic intercepts in the world, exceptional metallurgical recoveries, and a pipeline of catalysts ahead — including our upcoming mineral resource estimate — we believe a U.S. national exchange listing will unlock a significant re-rating opportunity and introduce this company to a broader community of institutional and retail investors.” — Terry Lynch, CEO, Power Metallic Mines Inc

Qualified Person

Joseph Campbell, P. Geo, VP Exploration at Power Metallic, is the qualified person who has reviewed and approved the technical disclosure contained in this news release.

About Power Metallic Mines Inc.

Power Metallic is a Canadian exploration company focused on advancing the Nisk Project Area (Nisk–Lion–Tiger)—a high–grade Copper–PGE, Nickel, gold and silver system—toward Canada’s next polymetallic mine.

On 1 February 2021, Power Metallic (then Chilean Metals) secured an option to earn up to 80% of the Nisk project from Critical Elements Lithium Corp. (TSX–V: CRE). Following the June 2025 purchase of 313 adjoining claims (~167 km²) from Li–FT Power, the Company now controls ~330 km² and roughly 50 km of prospective basin margins.

Power Metallic is expanding mineralization at the Nisk and Lion discovery zones, evaluating the Tiger target, and exploring the enlarged land package through successive drill programs.

Beyond the Nisk Project Area, Power Metallic indirectly has an interest in significant land packages in British Columbia and Chile, by its 50% share ownership position in Chilean Metals Inc., which were spun out from Power Metallic via a plan of arrangement on February 3, 2025.

It also owns 100% of Power Metallic Arabia which owns 100% interest in the Jabul Baudan exploration license in The Kingdon of Saudi Arabia’s Jabal Said Belt. The property encompasses over 200 square kilometres in an area recognized for its high prospectivity for copper gold and zinc mineralization. The region is known for its massive volcanic sulfide (VMS) deposits, including the world-class Jabal Sayid mine and the promising Umm and Damad deposit.

For further information, readers are encouraged to contact:
Power Metallic Mines Inc.
The Canadian Venture Building
82 Richmond St East, Suite 202
Toronto, ON

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

QAQC and Sampling

GeoVector Management Inc (“GeoVector”) is the Consulting company retained to perform the actual drilling program, which includes core logging and sampling of the drill core.

All core in this news release is either HQ or NQ sized core. Drill core is re-fitted and measured. Geotech on core includes photographs (wet & dry), rock quality index, magnetic susceptibility, conductivity, and recovery estimates. Core is logged for lithology, mineralogy, and structural features, and sample intervals are delineated and tagged.

Sampled core is mechanically sawn, and half-core is retained for future reference. GeoVector’s QAQC program includes regular insertion of CRM standards, duplicates, and blanks into the sample stream with a stringent review of all results. QAQC and data validation was performed, and no material errors were observed.

All samples were submitted to and analyzed at Activation Laboratories Ltd (“Actlabs”), a commercial laboratory independent of Power Metallic with no interest in the Project. Actlabs is an ISO 9001 and 17025 certified and accredited laboratories. Samples submitted through Actlabs are run through standard preparation methods and analysed using RX-1 (Dry, crush (< 7 kg) up to 80% passing 2 mm, riffle split (250 g) and pulverize (mild steel) to 95% passing 105 μm) preparation methods, and using 1F2 (ICP-OES) and 1C-OES – 4-Acid near total digestion + Gold-Platinum-Palladium analysis and 8-Peroxide ICP-OES, for regular and over detection limit analysis. Pegmatite samples are analyzed using UT7 – Li up to 5%, Rb up to 2% method. Actlabs also undertake their own internal coarse and pulp duplicate analysis to ensure proper sample preparation and equipment calibration.

Cautionary Note Regarding Forward-Looking Statements

This message contains certain statements that may be deemed “forward-looking statements” concerning the Company within the meaning of applicable securities laws. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential,” “indicates,” “opportunity,” “possible” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, are subject to risks and uncertainties, and actual results or realities may differ materially from those in the forward-looking statements. Such material risks and uncertainties include, but are not limited to, among others; the timing for various drilling plans; the ability to raise sufficient capital to fund its obligations under its property agreements going forward and conduct drilling and exploration; to maintain its mineral tenures and concessions in good standing; to explore and develop its projects; changes in economic conditions or financial markets; the inherent hazards associates with mineral exploration and mining operations; future prices of nickel and other metals; changes in general economic conditions; accuracy of mineral resource and reserve estimates; the potential for new discoveries; the ability of the Company to obtain the necessary permits and consents required to explore, drill and develop the projects and if accepted, to obtain such licenses and approvals in a timely fashion relative to the Company’s plans and business objectives for the applicable project; the general ability of the Company to monetize its mineral resources; and changes in environmental and other laws or regulations that could have an impact on the Company’s operations, compliance with environmental laws and regulations, dependence on key management personnel and general competition in the mining industry.

Release – Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models

Posted on by [email protected]
Tonix Pharmaceuticals Logo

Research News and Market Data on TNXP

July 15, 2026 9:05am EDT Download as PDF

Data show clade IIb from 2022 outbreak is 100 to 100,000-fold less virulent than clade IIa from 2003 outbreak

Three new models for investigating mpox infection and pathogenesis identified

Tonix is advancing TNX-801, a live, attenuated, minimally replicative investigational vaccine candidate based on horsepox virus to protect against mpox disease

BERKELEY HEIGHTS, N.J., July 15, 2026 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biotechnology company, today announced the publication of a paper, “Monkeypox virus clade IIb isolate exhibits reduced virulence relative to clade IIa isolates in multiple murine models,” in the Journal of Virology, the peer-reviewed publication of the American Society for Microbiology (ASM). The research, conducted at Tonix, found new animal models for investigating mpox pathogenesis and demonstrated significant differences in virulence between the clade IIb circulating in the U.S. and the historic 2003 clade IIa. The manuscript can be accessed at:
https://doi.org/10.1128/jvi.00247-26.

“Global mpox outbreaks that have caused severe human disease continue to occur due to previously unrecognized subclades,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “New approaches to understand and mitigate the spread of emerging mpox subclades are urgently needed. To examine the pathogenesis of emerging mpox clades, we identified three new murine models susceptible to mpox clade II infection, which revealed significant differences in virulence between clades. As Tonix investigates TNX-801 (live attenuated horsepox vaccine) for the prevention of mpox and smallpox, establishing additional foundational models are important to categorize and ultimately protect against the disease.”

“The decreased virulence of clade IIb may have contributed to its ability to spread worldwide,” said Sina Bavari, Ph.D., Executive Vice President of Tonix and site head of Tonix’s Research and Development Center (RDC) in Frederick, Maryland. “Indolent subclinical infection is a risk factor for unintentional spread. Importantly, a deeper understanding of mpox virus (MPXV) pathogenesis will help guide the continued development and positioning of the TNX-801 vaccine platform, a vaccine candidate against mpox. Tonix is committed to advancing the understanding of emerging mpox disease and to developing TNX-801 platform as a potential vaccine candidate to address the continuing global threat posed by mpox.”

Led by Farooq Nasar, Ph.D., Director, Virology, Tonix utilized its state-of-the-art research laboratory capabilities, including a Biosafety Level 3 (BSL-3) lab and an Animal Biosafety Level 3 (ABSL-3) facility, at RDC which is close to the center of the U.S. biodefense research community.

Mpox is an emerging human disease caused by four distinct MPXV subclades (Ia, Ib, IIa, and IIb). Despite their genetic similarities, the case fatality rates differ considerably among the subclades: Ia (~11%), Ib and IIa (~4%), and IIb (~0.2%). Since 2022, multiple mpox outbreaks caused by the previously unrecognized Ib and IIb subclades have led the World Health Organization to declare two Public Health Emergencies of International Concern. Cases are currently increasing in multiple regions of the Americas. This unprecedented global spread and the marked differences in disease severity among MPXV subclades underscore the importance of investigating the pathogenesis of emerging MPXV variants. However, a critical limitation has been the lack of suitable small animal models.

This publication expands on the previously established CAST/EiJ mouse model by evaluating susceptibility to MPXV subclade IIa and IIb infection in both 7- to 8-week-old and 4- to 5-month-old mice. The demonstrated susceptibility of older CAST/EiJ mice to clade IIa infection highlights the utility of this model for evaluating long-term vaccine durability and protective efficacy. In addition, the study describes three novel C57BL/6 mouse models deficient in the interferon-α receptor, interferon-γ receptor, or both receptors for the study of MPXV infection. The study demonstrates that the emerging clade IIb isolate is up to 100,000-fold less virulent than clade IIa isolates. Collectively, these models provide valuable new tools for rapidly investigating the pathogenesis of emerging MPXV subclades and evaluating medical countermeasures, including vaccines.

About Mpox

Mpox is an acute contagious disease caused by the monkeypox virus or MPXV, which is also a member of the orthopoxvirus family. Mpox is emerging as an important zoonotic infection in humans in Central and West Africa. Until 2022, only a few cases of mpox were reported outside of Africa in patients who had been infected while in Africa. Starting in May of 2022, mpox clade II cases spread rapidly in the U.S. and other countries. The World Health Organization (WHO) declared mpox clade IIb to be a public health emergency of international concern (PHEIC). The clade II mpox affects mostly men who have sex with men in the U.S., where it has become endemic. The WHO lifted PHEIC designation for clade Ib. In August 2024, the WHO declared mpox clade Ib to be a PHEIC due to an outbreak in the Democratic Republic of the Congo that spread globally, including to the U.S. clade Ib affects children and adults. Although the WHO has lifted PHEIC designation for clade Ib, mpox continues to spread in Africa, and mutations of the virus are considered by public health experts to be an ongoing threat to be monitored for new epidemic spread.

About TNX-801

TNX-801 (recombinant horsepox virus) is an attenuated, minimally replicative, live virus vaccine based on horsepox in pre-clinical development to prevent mpox and smallpox. TNX-801 is expected to enter a Phase 1 study in 2027 pending FDA clearance of an Investigational New Drug Application (IND). TNX-801 is in the pre-IND stages of development.

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) disorders, infectious diseases, immunology conditions, and rare diseases where there exists high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s flagship internally conceived and developed medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is extending the science behind TONMYA in Phase 2 clinical studies to evaluate the potential of TNX-102 SL in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of infectious disease programs, including monoclonal antibody TNX-4800 (anti-OspA mAb) for Lyme disease prevention in the U.S. and TNX-801 (horsepox, live virus vaccine), a vaccine in development for the prevention of mpox and smallpox. Tonix has been awarded a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Maryland. Within immunology, Tonix is developing TNX-1500 (anti-CD40L mAb), a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. Finally, the Company’s rare disease portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome. To learn more, visit www.tonixpharma.com.

*Tonix’s product development candidates, including TNX-102 SL for new, unapproved indications, are investigational new drugs or biologics. Their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the offering, the satisfaction of customary closing conditions, the intended use of proceeds from the offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize TONMYA® and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Contacts

Deborah Elson (Investors/Media)
Tonix Pharmaceuticals
[email protected]
[email protected]  

Brian Korb (Investors)
astr partners
(917) 653-5122
[email protected]

Andrea Cohen (Media)
Sam Brown Inc.
(917) 209-7163
[email protected]

Primary Logo

Source: Tonix Pharmaceuticals Holding Corp.

Released July 15, 2026

Release – Century Lithium Reports Lithium Metal From Angel Island Demonstrated in Battery Cells Under U.S. Army SBIR Program

Posted on by [email protected]
Century Lithium

Research News and Market Data on CYDVF

July 15, 2026 – Vancouver, Canada – Century Lithium Corp. (TSXV: LCE) (OTCQX: CYDVF) (Frankfurt: C1Z) (“Century Lithium” or “the Company”) is pleased to announce that lithium carbonate produced from its 100% owned Angel Island Lithium Project in Nevada, USA (“Angel Island”) was successfully converted into lithium metal using Alpha-En Corporation’s (“Alpha-En”) proprietary extraction and electrodeposition process and incorporated into cylindrical cells manufactured by EaglePicher Technologies (“EaglePicher”). This work was supported by funding from the US Army Small Business Innovation Research (“Army SBIR”) program, which aims to accelerate the development of innovative technologies critical to national defense.

“Alpha-En has done outstanding work converting lithium carbonate from Angel Island into high-purity lithium metal, which was then incorporated by EaglePicher in cells tested under the U.S. Army SBIR program,” said Bill Willoughby, President and CEO of Century Lithium. “The results from this first phase program are important for Century Lithium and further highlight Angel Island as a quality domestic source of lithium.”

The lithium metal anodes produced from Angel Island lithium carbonate by Alpha-En met EaglePicher’s performance specifications and were integrated into EaglePicher’s cylindrical cells for testing. Initial discharge results demonstrated higher operating voltages and improved power performance compared to the control cells, key attributes for demanding defense applications which require lightweight, high-energy, and high-power battery systems.

“This Army SBIR-supported effort demonstrates that high-performance lithium metal anodes can be manufactured directly from US-sourced lithium resources,” said Landon Oakes, Chief Technology Officer of Alpha-En. “By integrating domestic raw materials with our membrane extraction and electrodeposition platform, we are establishing a secure, vertically integrated pathway for next-generation battery anodes that reduces reliance on foreign supply chains.”

This successful demonstration represents a significant step toward strengthening the domestic defense battery supply chain. By connecting US-based lithium resources, advanced lithium metal manufacturing, and domestic cell fabrication, the collaboration supports the US Army’s objective of securing critical mineral independence while advancing high-performance battery technologies for future defense systems.

Qualified Person

The scientific and technical information contained in this news release has been reviewed and approved by Todd S. Fayram, MMSA-QP, Chief Technical Officer of Century Lithium, a non-independent Qualified Person under NI 43-101. The content in this news release has been approved by all parties mentioned.

ABOUT CENTURY LITHIUM CORP.

Century Lithium Corp. is an advanced-stage lithium development company focused on its 100%-owned Angel Island lithium project in Esmeralda County, Nevada. Angel Island hosts one of the largest known sedimentary lithium deposits in the United States and is designed with an integrated, end-to-end process for the on-site production of battery-grade lithium carbonate to support the electric vehicle and battery storage markets.

The Company has developed a patent-pending process that incorporates hydrochloric acid leaching combined with direct lithium extraction to produce battery-grade lithium carbonate. As part of the integrated chlor-alkali process, Angel Island is designed to produce sodium hydroxide as a co-product, with planned surplus sales expected to lower operating costs, reduce reliance on externally sourced reagents, and minimize environmental impacts.

Century Lithium is currently advancing Angel Island through the permitting process.

Century Lithium trades on the TSX Venture Exchange under the symbol “LCE” the OTCQX under the symbol “CYDVF”, and on the Frankfurt Stock Exchange under the symbol “C1Z”.

To learn more, please visit centurylithium.com.

ON BEHALF OF CENTURY LITHIUM CORP.

WILLIAM WILLOUGHBY, PhD., PE
President & Chief Executive Officer

For further information, please contact:
Spiros Cacos | Vice President, Investor Relations
Direct: +1 604 764 1851
Toll Free: 1 800 567 8181
[email protected]
centurylithium.com

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE.

Cautionary Note Regarding Forward-Looking Statements

This release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” and similar expressions suggesting future outcomes or statements regarding an outlook.

Forward-looking statements relate to any matters that are not historical facts and statements of our beliefs, intentions and expectations about developments, results and events which will or may occur in the future, without limitation, statements with respect to the potential development and value of the Project and benefits associated therewith, statements with respect to the expected project economics for the Project, such as estimates of life of mine, lithium prices, production and recoveries, capital and operating costs, IRR, NPV and cash flows, any projections outlined in the Feasibility Study in respect of the Project, the permitting status of the Project and the Company’s future development plans.

These and other forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein. These risks include those described under the heading “Risk Factors” in the Company’s most recent annual information form and its other public filings, copies of which can be found under the Company’s profile at www.sedarplus.ca. The Company expressly disclaims any obligation to update-forward-looking information except as required by applicable law. No forward-looking statement can be guaranteed, and actual future results may vary materially. Accordingly, readers are advised not to place reliance on forward-looking statements or information. Furthermore, Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability.

Biotech IPOs Doubled in the First Half of 2026. The Funding Window for Small Cap Drug Developers Has Not Been This Wide in Years

Posted on by [email protected]

The biotech sector spent the better part of three years locked out of the public markets. That era appears to be decisively over. Eighteen biotech companies completed initial public offerings in the first half of 2026, exactly double the eight that went public during the same period in 2025, according to data from BioSpace. Two of those listings, Kailera Therapeutics at $625 million and Parabilis Medicines at $670 million, shattered the previous record for the largest biotech IPO ever, a title Moderna had held since 2018.

The numbers are not just higher in volume. They are higher in conviction. The median biotech IPO in 2026 raised approximately $287.5 million, more than double the equivalent figure from early 2025 and the highest quarterly median since the pandemic-era peak of 2021. Eleven of the thirteen venture-backed biotechs that priced offerings in the first half secured at least $250 million. Investors are writing larger checks for fewer companies, and the companies receiving that capital are performing after they get to Wall Street. Most of the 2026 class is currently trading at or above its debut price.

Why the Window Opened

Two forces converged to create this environment, and they are reinforcing each other. The first is a surge in mergers and acquisitions. In Q1 2026 alone, the biopharma sector recorded 19 exits valued at $13.3 billion, the highest exit value since the fourth quarter of 2021. Deals like GSK’s $10.6 billion acquisition of Nuvalent and AbbVie’s $10.9 billion purchase of Apogee Therapeutics have demonstrated that large pharma will pay significant premiums for clinical-stage assets in high-priority therapeutic areas. That M&A activity is directly fueling IPO appetite because the companies going public increasingly resemble the exact profiles that large pharma is hunting.

The second force is a return to regulatory predictability at the FDA. The agency has moved toward greater use of advisory committees and is re-evaluating applications that previously received complete response letters, creating a more navigable path for companies with mid-to-late-stage clinical programs. The combination of active acquirers and a more transparent regulatory environment has restored investor confidence in the sector’s ability to generate returns.

What It Means for Existing Small Cap Biotechs

The implications extend well beyond the companies actually going public. A healthy IPO market lifts the entire clinical-stage biotech ecosystem. When newly public companies trade well, it signals to institutional investors that the sector is functioning again, which draws capital back into the broader small cap biotech universe, including the hundreds of companies already listed and advancing their own programs.

The therapeutic areas attracting the most capital align closely with where patent cliffs are creating the most urgency for large pharma acquirers. Oncology remains a dominant focus, with companies like Cardiff Oncology, MAIA Biotechnology, and Greenwich LifeSciences all advancing clinical programs in areas where large pharma has demonstrated a clear willingness to pay for innovation. Cardiovascular disease emerged as a significant theme in H1, with Kardigan’s $400 million offering anchored around late-stage cardiac assets. Immunology, neuroscience, and rare disease continue to draw investor interest as well, with companies like Eledon Pharmaceuticals developing differentiated programs in therapeutic areas where unmet need and commercial opportunity intersect.

The second half is expected to accelerate further. Nasdaq has estimated that a dozen additional biotech IPOs could price in Q3 alone, and companies like Scribe Therapeutics, co-founded by CRISPR pioneer Jennifer Doudna, are already in the filing process. The biotech funding window has not been this open since 2021. The difference this time is that the market is rewarding discipline, clinical data, and clear regulatory paths rather than early-stage platforms and promises. That distinction is what makes this cycle more durable than the last one.

Release – Kratos Opens New 167,000-Square-Foot Manufacturing Facility in Pennsylvania, Expanding Existing Footprint in the State

Posted on by [email protected]
Primary Logo

Research News and Market Data on KTOS

July 15, 2026

PDF Version

Kratos’ Pennsylvania Operations Engineer, Manufacture and Test Mission-Critical, Military-Grade Hardware Supporting Certain of the Nation’s Highest-Priority Hypersonic, Air Defense, Missile, Radar and Counter-Unmanned Aircraft System (C-UAS) Programs

Kratos’ Expanded Pennsylvania Operations Accelerate Development and Large-Scale Mass Production of Mil-Spec Hardware to Strengthen National Security

SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company specializing in defense, national security and global markets, today announced the opening of a 167,000-square-foot advanced manufacturing facility in York, Pennsylvania. The plant expands Kratos’ existing Pennsylvania operations, which now span three facilities and employ more than 440 people, supporting a growing portfolio of critical national security programs. Additionally, Kratos announced plans to purchase new state-of-the-art equipment, totaling over $7 Million, to further expand production capability.

The new facility and planned investments in manufacturing equipment significantly increase Kratos’ production capacity to meet accelerating customer demand for advanced defense systems while reinforcing the company’s commitment to strengthening the U.S. defense industrial base through rapid innovation and mission-speed production.

Kratos’ Pennsylvania operations engineer, manufacture and test mission-critical, military-grade hardware supporting certain of the nation’s highest-priority air defense, missile, radar and counter-unmanned aircraft system (C-UAS) initiatives. Including the new facility, Kratos’ Pennsylvania operations actively support C-UAS initiatives by delivering complex equipment for directed energy weapons, missile transporters, mobile missile launcher systems, hypersonic systems and strategic system radar platforms.

Tom Mills, President of Kratos C5ISR Division, said, “Leveraging proven manufacturing methodologies and advanced production technologies, Kratos’ Pennsylvania operations recently completed delivery of highly engineered solutions for both High Power Microwave (HPM) and High Energy Laser (HEL) programs. These efforts included the design, manufacture and testing of specialty structures and components that enhance system mobility and survivability, along with system integration involving custom mechanical assemblies, actuators, thermal management and electrical subsystems. This new Kratos facility and investment will both expand and accelerate our capabilities in additional mission critical national security programs, including strategic systems”.

“Kratos is committed to building the Arsenal of Freedom by investing in the people, facilities and manufacturing capabilities needed to deliver critical systems, at scale, to our customers faster than ever before,” said Eric DeMarco, President and CEO of Kratos. “This expansion marks another important milestone in continuing to grow Kratos’ capability to provide mil-spec hardware for national defense and mission critical programs. Pennsylvania has proven to be an exceptional manufacturing hub, including a highly skilled workforce, and this investment positions Kratos to continue delivering affordable, high-performance, leading technology systems that address our nation’s most pressing security challenges. Kratos’ ability to manufacture highly complex hardware at production scale—where quality, precision and reliability are mission-critical—continues to differentiate our Company as a trusted partner to the U.S. Department of War and allied customers.”

The new facility and related manufacturing equipment provides expanded space and capabilities for advanced manufacturing, systems integration and testing, enabling Kratos to scale production while meeting increasing customer requirements for speed, affordability and performance.

Kratos’ expansion in Pennsylvania represents the company’s continued investment in American manufacturing and its commitment to delivering warfighter-ready capabilities that outpace evolving threats while strengthening the nation’s defense industrial base.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value-add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com and follow Kratos on LinkedIn and X.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 28, 2025, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Claire Cantrell
[email protected]

Kratos Investor Information:
877-934-4687
[email protected]